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Abstract
Objective: Mild neurocognitive disorders (MND) affect a subset of HIV+ patients under effective combination antiretroviral
therapy (cART). In this study, we used an innovative multi-contrast magnetic resonance imaging (MRI) approach at high-
field to assess the presence of micro-structural brain alterations in MND+ patients.
Methods: We enrolled 17 MND+ and 19 MND2 patients with undetectable HIV-1 RNA and 19 healthy controls (HC). MRI
acquisitions at 3T included: MP2RAGE for T1 relaxation times, Magnetization Transfer (MT), T2* and Susceptibility Weighted
Imaging (SWI) to probe micro-structural integrity and iron deposition in the brain. Statistical analysis used permutation-
based tests and correction for family-wise error rate. Multiple regression analysis was performed between MRI data and (i)
neuropsychological results (ii) HIV infection characteristics. A linear discriminant analysis (LDA) based on MRI data was
performed between MND+ and MND2 patients and cross-validated with a leave-one-out test.
Results: Our data revealed loss of structural integrity and micro-oedema in MND+ compared to HC in the global white and
cortical gray matter, as well as in the thalamus and basal ganglia. Multiple regression analysis showed a significant influence
of sub-cortical nuclei alterations on the executive index of MND+ patients (p = 0.04 he and R2 = 95.2). The LDA distinguished
MND+ and MND2 patients with a classification quality of 73% after cross-validation.
Conclusion: Our study shows micro-structural brain tissue alterations in MND+ patients under effective therapy and
suggests that multi-contrast MRI at high field is a powerful approach to discriminate between HIV+ patients on cART with
and without mild neurocognitive deficits.
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Introduction
It has been suggested that HIV encephalitis is the neuropath-
ological substrate of cognitive disorders [1]. Although HIV does
not directly infect neurons or oligodendrocytes, this virus can
trigger an inflammatory response with release of cytokines,
chemokines, and neurotoxic HIV viral proteins (e.g. gp120)
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[1,2], leading to inflammatory infiltrates, as well as myelin and
neuronal loss [3,4]. Since the seeding of HIV in the brain occurs
early after infection [5], it is possible that HIV-triggered neuro-
inflammatory changes occur in the early stages of the disease.
Furthermore, combination antiretroviral therapy (cART) may not
be sufficient to prevent neuro-inflammatory damages triggered by
HIV since some anti-retroviral drugs have a poor rate of
penetration-effectiveness into the central nervous system (CNS)
[6]. On the other hand, some cART compounds with good
penetration might be neurotoxic and provoke cognitive disorders
in patients with long-standing treatment [7,8].
In this study, we used a multi-contrast approach at 3 T in a
population of HIV patients well treated with cART (undetectable
viral load) with and without cognitive impairments (MND+ and
MND2) as well as a population of healthy sero-negative controls
(HC).
The aim of the study was to determine if MND+ patients
showed micro-structural brain alterations, changes in myelination
integrity and iron deposition compared to MND2 and HC. In this
context, we tested the null hypotheses that there are no differences:
1) in micro-structural integrity of global white matter (WM) and
cortical gray matter (cGM) among MND+, MND2 and HC (ii) in
micro-structural integrity of sub-cortical nuclei involved in
cognitive function (basal ganglia and thalamus) and (iii) in
micro-structural integrity of WM and cGM in the frontal, parietal,
temporal and occipital lobes.
Lastly, we assessed the null hypothesis that no correlation
existed between MRI markers of micro-structural alterations in
patients and (i) cognitive signs as well as (ii) HIV infection
characteristics.
Methods
Subject population
Thirty-six age-matched HIV+ patients with undetectable HIV-1
RNA concentrations (,20 copies/ml for .3 months before study
entry) were enrolled: 17 MND+ (53.669.1 years, 13 males-M and
4 females-F) and 19 MND- (4967.2 years, 15 M and 4 F). All
participants were enrolled in a randomized pilot study testing the
efficacy of rivastigmine on MND and all the MRI were acquired
before the beginning of the therapy. The HIV viral load was
measured in the cerebrospinal fluid (CSF) of MND+ patients and
was undetectable in all of them. We did not examine the CSF of
MND2 patients because of ethical reasons (absence of complaints
and deficits). All patients were treated with cART.
According to the Frascati criteria [9], HIV+ patients were
considered as MND+ when they exhibited deficits in $2 cognitive
domains (performance #1 standard deviation below the stan-
dardized norms on neuropsychological tests) associated with
evidence for mild decreased everyday functioning. Patients with
HIV associated-dementia and asymptomatic neurocognitive im-
pairment were not considered for the study. Other exclusion
criteria were: (1) history of CNS opportunistic infection, (2) any
other opportunistic infection not affecting the brain in the last
12 months before study entry, (3) active drug use, and (4) major
depression according to DSM-IV criteria.
Nineteen sero-negative healthy controls (HC: 5068 years, 9 M
and 10 F) were also enrolled in the study. Since none of the HC
subjects had cognitive complaints, which has been reported to
strongly correlate with normal cognitive functioning in HIV2
subjects [10], we only performed a general measure of cognitive
function using the mini-mental state examination (MMSE $25,
HC: 2862) in this category of study subjects, without additional
neuropsychological examination. The study was approved by the
Ethics Committee of the Lausanne University Hospital (CHUV)
and all subjects gave informed written consent for their
participation.
Neurobehavioral examination in patients
Neuropsychological testing. All HIV+ participants under-
went a comprehensive neuropsychological evaluation, assessing
five cognitive domains generally impaired in HIV+ patients with
HIV-associated neurocognitive disorder (HAND) [9,11]. The
functions examined and the applied referenced tests are reported
in detail in Table 1. A deficit score for each domain was then
calculated using z-scores retrieved from available normative data
correcting for age, gender and educational level.
Psychiatric examination. A psychiatric interview using a
French questionnaire (Questionnaire de Sante´ du Patient) was
conducted in order to look for the presence of mood disorders
according to the DSM-IV diagnostic criteria. Current mood was
assessed using the Hospital Anxiety and Depression scale
addressing depressive (HAD-D) and anxious (HAD-A) symptoms,
separately. Patients were considered depressed/anxious if the
HAD-D/HAD-A subscale score was $10/21[11,12].
Table 1. Neuropsychological tests. References are reported in Data S1.
COGNITIVE TESTS TESTED FUNCTION REFERENCES
1. Reaction Time (RTI) from the Cambridge Neuropsychological Test Automated Battery
(CANTAB)
speed of information processing [11], [42], [43]
2. Trail Making Test part A (TMT-A)
3. Rapid Visual Information Processing [RVIP] attention/working memory [11], [42], [43] ,[44]
4. Spatial Working Memory (SWM-Error component) from the CANTAB
5. Digit spans backward and forward
6. Trail Making Test part B (TMT-B) executive functioning [11], [42], [45] ,[43]
7. Stockings of Cambridge (SOC) from the CANTAB
8. Spatial Working Memory (SWM-Strategy component) from the CANTAB
9. Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) verbal learning/memory [11], [42], [46]
10. Reaction Time (RTI, motor component) from the CANTAB motor skills
11. HIV Dementia Scale (HDS) International HDS (IHDS) screening scales [11], [42], [47], [48]
doi:10.1371/journal.pone.0072547.t001
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Functional assessment. The impact of cognitive difficulties
on everyday functioning was evaluated through the self-assessment
of HIV+ patients. In addition, we conducted the Medical
Outcome Study HIV Health Survey (MOS HIV), a questionnaire
assessing health-related quality of life (QoL).
MRI acquisition
All examinations were carried out on a 3T Magnetom Trio a
Tim System (Siemens, Erlangen, Germany) equipped with a 32-
channel head coil. A high-resolution T1-weighted Magnetization
Prepared Rapid Gradient Echo (MPRAGE) was acquired for
anatomical reference (TR/TE =2300/2.84 ms, inversion time
TI= 900 ms, voxel size = 16161.2 mm3, matrix size
= 25662406160) [13]. A MP2RAGE acquisition with the same
voxel and matrix size was used to assess T1 relaxation maps (TR/
TE =5000/2.84 ms, inversion times TI1= 700 ms and
TI2= 2500 ms, FA1= 4u, FA2= 5u) [14] (Figure 1 A). Multiple
echo Fast Low Angle SHot Magnetic Resonance Imaging
(FLASH) with and without magnetization transfer preparation
was acquired (TR/TE =48/23 ms, voxel size = 26262 mm3,
FoV =2406256696, 8 echoes) as described previously [15]. The
signals acquired with (MT) and without (M0) the magnetization
saturation pulse were used to compute Magnetization Transfer
Ratio (MTR) maps, (MTR = (M02MT)/M0*100, Figure 1 B).
The 8 echoes of the M0 volumes were used to compute T2 * maps
by fitting a mono-exponential decay (Figure 1 C).
Susceptibility Weighted Images (SWI) were acquired in a subset
of patients and controls (MND+ n= 14, 53.569.3 years, 12 M and
2 F, MND2 n= 16, 4866.4 years, 13 M and 4 F and HC n=5,
28.6612.5 years, 3 M and 2 F) using a velocity compensated 3D
gradient echo sequence (TR=50/30 ms, FA = 18u, voxel size
0.760.761.4 mm3, matrix size = 1806220652). Phase images
were high-pass filtered to correct for low-frequency phase
variations [16].
The MRI protocol (including the SWI sequence) was approved
by the ethic committee and performed only after obtaining written
consent from all participants.
Concepts of quantitative and semi-quantitative MRI
contrasts
The MTR is a semi-quantitative marker of structural integrity,
which is sensitive to the relative proportion of macromolecules
(myelin and cellular proteins) and water [17]. A reduced MTR
indicates therefore a loss of macromolecules and/or microscopic
oedema [17].
Similarly, the quantitative T1 assessment probes micro-struc-
tural properties and longer T1 values indicate a loss in tissue
structure (macromolecules) [18,19]. On the other hand, the
presence of small molecules with high rotational speed might
Figure 1. Quantitative/semi-quantitative maps and segmentation in regions of interest. Color coded T1 (A), MTR (B) and T2* (C) maps
showing the distribution of the contrasts in an axial slide; In (D), region of interest segmentation of global gray matter (brown), white matter (green),
thalamus (pink), caudate (blue), putamen (cyan) and globus pallidus (yellow) in one MND+ subject.
doi:10.1371/journal.pone.0072547.g001
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shorten the T1 relaxation times. In addition, quantitative T1
measurements are biased by local iron presence, with higher levels
of iron leading to shorter T1 values [18,19]. Similarly, T2*
relaxation times strongly depend on the local iron content with
high iron leading to shortened T2* values [19]. Lastly, the phase
information derived from SWI data provides complementary
information to the T2* measurement as it is sensitive to myelin
alterations and iron accumulation [20].
Image processing
Bias-field correction and tissue classification were performed on
the MPRAGE volumes using an in-house segmentation tool based
on a Variational Expectation-Maximization algorithm [21]. The
following 6 regions-of-interest (ROI) were extracted in a fully
automated fashion: global white and cortical gray matter (WM and
cGM), thalamus, caudate, globus pallidus and putamen (Figure 1 D).
Subsequently, T1, MTR and T2* maps were aligned to the
MPRAGE volume by a rigid-body registration with 6 degrees of
freedom and mutual information cost function using ELASTIX
[22]. Rigid and non-rigid registration [23,24] were performed to
align an in-house template (obtained by manual correction of a
segmentation provided by Freesurfer software www.surfer.nmr.
mgh.harvard.edu in a single healthy subject) to the MPRAGEs
volumes. Average MTR, T1 and T2* values were obtained for all
ROIs.
In order to minimize registration and partial volume errors: (i)
visual inspection and eventual manual correction of deep gray
matter nuclei was performed by an experienced neurologist (GC)
(ii) a threshold obtained by taking + and 23 standard deviations
from the mean value of T1, T2*, MTR histograms in each single
ROI in the healthy control group was applied to T1, T2* and
MTR values and (iii) morphological erosion was applied on the
binary segmentation masks using a disk with 2 voxels radius as
structuring element. A 3 voxel radius resulted to be inappropriate
for small ROIs like the basal ganglia. In this ways, we tried to
verify the influence of possible contaminations from other tissue
types. Statistical significance did not change after applying the
threshold and the erosion, therefore the original results are
reported.
Volumetric information was computed for all the 6 ROIs
mentioned above and for WM and cGM of each lobe (frontal,
parietal, temporal and occipital). Each volume was normalized by
the total intracranial volume (TIV).
SWI data were analyzed using manual delineation of ROIs in
the thalamus, caudate, globus pallidus and putamen (ROI size between
143 and 190 mm3) in order to avoid susceptibility artifacts at the
periphery of these structures, which would have hampered the
automatic analysis. Phase differences to CSF (assumed to have
zero iron content) were used to assess possibly iron related phase
accumulations in each nucleus.
Statistical analysis
Differences in age, gender and educational levels were assessed
using a non-parametric ANOVA (Kruskal-Wallis test) among
MND+, MND2 and HC. Differences in HIV-infection charac-
teristics (disease duration since diagnosis, duration of aviremia,
nadir of CD4 cell count and cART composition) were assessed
using Mann Whitney tests between MND+ and MND2 and
Bonferroni correction for multiple comparisons.
Non parametric ANOVA was used to assess volumetric
differences among all the ROIs.
Statistical analysis of parametric MRI data was performed
among the 3 groups (MND+, MND2 and HC) using permuta-
tion-based univariate t-tests (T1, MTR, T2*), bi-variate tests (T1-
MTR, MTR-T2* and T1–T2*) as well as multivariate Hotelling
tests (T1, MTR and T2*), with 10.000 permutations and age and
gender as covariates. Correction for family-wise error rate was
performed for multiple comparisons. SWI data were not used for
this analysis, because they were available only in a subset of
patients and controls.
Multiple regression analysis was performed to assess the
influence of MTR, T1, T2* values in all ROIs on global indexes
of impairment (cognitive impairment, processing speed, attention,
executive, motor and memory index) in MND+ patients. Age and
gender were included as covariables.
Similarly, multiple regression analysis was performed to assess
the influence of HIV and therapy-dependent characteristics
(disease duration, nadir CD4+, aviremia duration, cART dura-
tion) on the MTR, T1 and T2* values in all ROIs.
A linear discriminant analysis (LDA) based on T1, MTR and
SWI data was performed using the R-software (www.r-project.
org). LDA is a statistical procedure to find a linear combination of
features that characterizes or separates two or more classes of
objects and events [25]. A leave-one out test was performed for
cross-validation of prediction.
Results
HIV + patients, either MND+ or MND2, did not differ from
HC in age, education and gender (p.0.3, 0.3 and 0.07,
respectively).
MND+ and MND2 groups did not differ in age, gender,
educational level and HIV-characteristics (disease duration since
diagnosis, duration of aviremia, current CD4 T-cells count, nadir
CD4, cART composition) (Table 2). In particular, there was a
similarly high level of CD4+ T cells (.600/ml) and a CPE greater
than 7 in both categories, indicating that both MND+ and
Table 2. Demographics, HIV characteristics and
neuropsychological results (raw scores and indexes) of MND+
and MND2 patients.
MND+
(n =17)
MND-
(n =19) p-value
Age, y 53.669.1 4967.2 0.1
Gender, men (%) 13 (76) 16 (84) 0.6
Education ($ secondary school), n (%) 12 (71) 18 (95) 0.1
Duration of HIV infection, y 13.667.3 14.766.7 0.7
Duration of HIV aviremia, y 4.963.5 6.463.7 0.2
CD4+/ml 648.86217.3 647.16341.3 0.5
Nadir CD4+/ml 165.4688.7 198.46124 0.6
CPE score for current cART 7.661.9 7.361.7 0.7
HDS score 9.463.8 14.162.8 ,0.001
IHDS score 962.1 10.861.4 ,0.01
ADAS-Cog 7.162.9 3.261.3 ,0.001
Global cognitive index 15.664.8 3.761.7 ,0.0001
Processing speed index 3.361.8 1.361 ,0.01
Attention/working memory index 6.862.4 1.461.2 ,0.0001
Executive index 3.161.2 0.760.7 ,0.0001
Memory index 1.661.1 0.160.3 ,0.0001
Motor index 0.861.1 0.260.4 0.1
doi:10.1371/journal.pone.0072547.t002
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MND2 were immunocompetent and optimally treated. Further-
more, there was no difference with regard to potentially
neurotoxic drugs (see Table S1).
Yet, MND+ patients showed significantly lower scores in all
cognitive indexes than MND2 patients after Bonferroni correc-
tion for multiple comparisons (Table 2).
MRI analysis
Figure 2 and 3 shows the results of the comparison among
groups as well as their statistical significance (figures 4 and 5).
Univariate analysis showed (i) lower MTR in WM, cGM,
thalamus and caudate as well as (ii) lower T1 in all regions but
the thalamus when MND+ patients where compared to HC.
The same analysis showed (i) lower MTR in cGM and (ii) lower
T1 in WM and cGM of MND2 patients vs HC. The
univariate comparison between MND+ and MND2 patients
revealed additionally lower MTR in WM of MND+ subjects
and higher T2* in the caudate of MND2 patients (figures 2, 3,
4, and 5).
In addition, bivariate and multivariate analysis showed that
combination of contrasts revealed significant differences in all
regions for MND+ patients vs controls as well as in WM, cGM and
caudate of MND2 patients vs controls (figures 4 and 5).
No lobar predominance of WM and cGM changes was
observed (figures 3 and 5).
In summary, therefore, our data refute the 3 null hypotheses.
No volumetric differences were seen among groups in
WM, cGM, sub-cortical nuclei and lobar cgM and WM (see
Table S2).
Figure 2. Boxplots representing data from the univariate analysis for WM, cGM, thalamus and basal ganglia. In each box, the central
mark represents the median, the edges represent the 25th and 75th percentiles and the whiskers extend to the most extreme data points not
considered outliers; outliers are plotted individually as x. HC: green; MND2: red; MND+: blue.
doi:10.1371/journal.pone.0072547.g002
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Multiple regression analyses between MRI markers and
neuropsychological indexes in MND+ patients
We found that T1, T2* and MTR values in the sub-cortical
nuclei were correlated with the executive index in MND+
patients (p = 0.01 and multiple R2 = 0.95, adjusted R2= 0.85).
In particular, the parameters that were mostly correlated were
the MTR in the putamen (p = 0.05) and the T1 in globus
pallidus and putamen (p = 0.03). Age and gender did not
appear to play any significant effects on the executive index
(p.0.5).
Multiple regression analyses between MRI markers and
biological variables in HIV+ patients
We found that biological variables related to HIV infection were
not correlated with MRI markers of disease.
Linear discriminant analysis to differentiate between
MND+ and MND- based on MRI data
The linear discriminant analysis based on T1, MTR and SWI
data distinguished MND + from MND-patients with a classifica-
tion quality of 73% after cross-validation (specificity = 76.5% and
sensitivity = 69%). T2* data did not add any significance to the
model.
Figure 3. Boxplots representing data from the univariate analysis for lobar WM and cGM. In each box, the central mark represents the
median, the edges represent the 25th and 75th percentiles and the whiskers extend to the most extreme data points not considered outliers; outliers
are plotted individually as x. HC: green; MND2: red; MND+: blue. FWM: frontal WM; PWM: parietal WM; TWM: temporal WM; OWM: occipital WM;
FcGM: frontal cGM; PcGM: parietal cGM; TcGM: temporal cGM; OcGM: occipital cGM.
doi:10.1371/journal.pone.0072547.g003
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Discussion
Our study shows the presence of diffuse micro-structural brain
tissue alterations in MND+ and MND2 HIV+ patients
compared to a population of HIV2 healthy controls, despite
effective treatment and undetectable viremia and virorachia.
Most of the observed alterations were more pronounced in
MND+ than in MND2 patients and were significantly more
severe in global WM.
Biological substrate of MTR, T1 and T2* changes
We provide evidence of a significant decrease of MTR in
MND+ patients compared to HC in WM, cGM, thalamus and
caudate, whereas MND2 patients show a less prominent decrease
of MTR in cGM (Figures 2 and 4 A–B). Lower MTR indicates a
loss of macromolecules (myelin and cellular proteins) and/or a
micro-oedema effect [26,27], phenomena that are consistent with
an on-going inflammation triggered by HIV [28].
On the other hand, we observe longer T2* relaxation times in
the caudate of MND2 patients compared to MND+ patients; the
same patter was observed when MND2 patients were compared
Figure 4. Graphs showing the respective significance in each ROI for univariate analysis (loop), bivariate analysis (straight line) and
multivariate analysis (central circle). Red color indicates p#0.01 and yellow color indicates p#0.05. A) hypothesis 1, B) hypothesis 2.
doi:10.1371/journal.pone.0072547.g004
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to HC but it did not reach significance (Figures 2 and 4 B). .
Whether this aspect plays a role in the pathophysiology of MND
and/or in the development of HIV infection and response to
cART should be determined in prospective studies.
As to the T1 contrast, its behaviour is complex; based on the
MTR and T2* behaviour, we would have expected a general
increase in T1 in HIV+ patients vs. HC. However, T1 relaxation
times in MND2 and MND+ patients are generally shorter than
Figure 5. Graphs showing the respective significance in each ROI for univariate analysis (loop), bivariate analysis (straight line) and
multivariate analysis (central circle). Red color indicates p#0.01 and yellow color indicates p#0.05. Hypothesis 3.
doi:10.1371/journal.pone.0072547.g005
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HC (Figures 2, 3, 4, and 5), a behaviour that might reflect lower
iron content (above all in the presence of longer T2*) and/or the
presence of small non-paramagnetic molecules with high rota-
tional speed (tissue debris, cART compounds, etc) [18,29] that
would not influence T2* relaxation times.
Clinical implication of MTR, T1 and T2* changes in
aviremic HIV+ patients
Previous clinical studies reported that cognitive impairment in
HIV-infected individuals can occur in the context of maximal viral
suppression in the serum [30–33]. Some of these studies showed a
correlation between cognitive deficits and age [31,32]. Other
works suggested that cognitive impairment may be an effect of
HIV-induced accelerated aging [34] or neurodegenerative pro-
cesses dependent on chronic inflammation [35]. Recent studies
additionally proposed that insufficient penetration of cART in the
CNS [6] or, on the contrary, a drug-dependent toxic effect [8]
might play a role in MND physiopathology in aviremic HIV+
patients.
Nevertheless, MND+ and MND2 patients enrolled in our study
did not differ in terms of age, gender, nor for any HIV-related
characteristics (undetectable plasma HIV viral load in all, current
CD4+ T cell count, CD4+ nadir, duration of aviremia, cART
CPE score[6] as well as composition and duration). Furthermore,
the HIV viral load in the CSF was negative in all MND+ patients,
suggesting that there was no overt HIV replication in the CNS.
In this context, therefore, neither current HIV infection nor
drug response or toxicity appears to be a clear cause of the
presence of MND.
Thus, how to explain that some of these well-treated HIV+
patients develop MND and other not? We show that the micro-
structural differences between HC and MND+ are located in
regions particularly prone to HIV infection (WM and basal
ganglia) [30] as well as in multiple lobes of the cerebral cortex,
which have been previously shown to be thinner in HIV+ patients
with cognitive impairment [31,32]. Thus, despite the fact that
there is no difference in terms of HIV characteristics between
MND+ and MND2, we hypothesize that, upon HIV infection,
some patients are less able than others to control HIV replication
or to limit its collateral damages. This relative inefficiency will lead
to chronic low grade inflammation and tissue damage causing
cognitive disorders.
In favour of this hypothesis, we point to the strong correlation
between MRI results in the sub-cortical gray matter nuclei
(putamen and globus pallidus) and executive impairment. Deficits
in executive function have been largely described in untreated
HIV+ patients [9,36] as a consequence of HIV infection in the
basal ganglia and deep white matter. And previous studies showed
that fronto-striatal circuits connecting the lateral-prefrontal cortex
to the caudate and glubus pallidus play a major role in executive
functions (for review see [37]), and the putamen has been recently
reported to be implicated in working memory processes [38].
To date, there are no post-mortem studies reporting chronic
inflammation markers in the brain of HIV+ patients under
effective cART; the few studies available on treated HIV+ patients
did not include aviremic subjects and reported aspecific brain
pathology, which did not relate to premortem neurocognitive
deficits [39,40]. Future works should help elucidate the presence of
subtle chronic inflammatory processes and/or neurodegeneration
in the brain of well-treated HIV+ patients with MND.
Potential of multi-parametric MRI to study subtle brain
abnormalities
Previous MRI studies reported volumetric and morphometric
changes of the whole brain, basal ganglia and white matter in HIV
patients that correlated with cognitive symptoms (for review see
[41]). Notwithstanding, none of these previous works specifically
studied MND+ patients under effective cART and with undetect-
able viral load. Our study does and shows that multi-parametric
MRI at 3T is more sensitive than volumetric analysis to investigate
the presence and the nature of subtle abnormalities.
Last, another important finding of our study is that a linear
discriminant analysis based on T1, MTR and SWI data shows that
multi-parametric MRI provides the capability to distinguish
between MND+ and MND2 patients, even when both categories
are optimally treated, reaching classification quality of 73% after
cross-validation. This result is particularly important as it
evidences the potential future role of new clinically-compatible
MRI approached to support diagnostic processes in the absence of
neuropsychological expertise as well as to monitor response to
therapy and disease evolution.
In summary, multi-parametric MRI at high field appears a
powerful means to investigate the physiopathology of minor
neurological signs and a promising sensitive tool to support
medical diagnosis and follow-up. Future validation of these
methods is planned on a prospective study in Lausanne neuro-
HIV cohort.
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